Ger­man can­cer biotech BioN­Tech rais­es a mam­moth $325M in lat­est round, bring­ing to­tal haul to $1.4B+

With sev­en clin­i­cal as­sets, a string of key part­ner­ships with ti­tans of the phar­ma­ceu­ti­cal in­dus­try and whis­pers about a po­ten­tial IPO, Ger­man can­cer drug de­vel­op­er BioN­Tech on Tues­day un­veiled a her­culean $325 mil­lion in an up­sized round of fi­nanc­ing, mark­ing one of the largest sin­gle pri­vate fund­ing rounds for a biotech­nol­o­gy com­pa­ny in Eu­ro­pean his­to­ry.

“If you add all the bits and bobs we’ve col­lect­ed through Eu­ro­pean grants in the ear­ly days through to the up­front from are col­lab­o­ra­tions when we signed them and se­ries…fund­ing,  I think we’re just over $1.4 bil­lion now in to­tal cap­i­tal flows to the com­pa­ny,” not­ed Sean Marett, BioN­Tech’s chief busi­ness and com­mer­cial of­fi­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER